ScholarIQanswers from OpenAlex & ORCID
Harpreet Wasan
ResearcherPublications, citations & collaboration network
Harpreet Wasan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Harpreet Wasan have?
ScholarIQindexed works
Harpreet Wasan has 430 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Harpreet Wasan have?
ScholarIQcitation count
Harpreet Wasan has 31,231 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Harpreet Wasan?
ScholarIQh-index
Harpreet Wasan has an h-index of 67 in OpenAlex.
What is the i10-index of Harpreet Wasan?
ScholarIQi10-index
Harpreet Wasan has an i10-index of 201 in OpenAlex.
What is the ORCID of Harpreet Wasan?
ScholarIQorcid
The ORCID for Harpreet Wasan is on the source record.
What is the OpenAlex record for Harpreet Wasan?
ScholarIQopenalex
The OpenAlex for Harpreet Wasan is on the source record.
What are the most-cited papers on Harpreet Wasan?
ScholarIQmost cited works
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet Wasan, Peter Gibbs, Navesh Sharma, Julien Taı̈eb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S. Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson